Posts tagged ‘CSIQ’
Stocks on the Move Volume spike premarket
Pharmacyclics (PCYC) released preliminary results of its rights offering to purchase up to 22.5M shares of the Company’s common stock at a subscription price of $1.28 per share.
Affymax (AFFY) releaseds Q2 EPS ($1.17) vs. consensus of ($1.27)
Reports Q2 revenue $26.92M vs. consensus of $25.32M.
Whole Foods(WFMI) at 52week high which is about 50% of the 2007 highs. The companyt released earnings which were better than expected. We had over 1 million shares trade hands after the report after the close yesterday.
Novavax,Inc. (Nasdaq:NVAX) pre market spike on volume. This biotech company makes a virus particle vaccine that works on H1N1 influenza. Novavax has produced essential reagents for measuring vaccine potency and also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies. Shares are up a sharp 23% at $5.76 in trading as of 8:15 AM EST on 657,000 shares.
American Capital Ltd. ACAS is looking like a short this morning The businesses posted a $547 million second-quarter loss and is outside of its covenants. The loss came to -$2.52 EPS and net operating income fell 86% to $20 million or $0.09 EPS
Big 5 (BGFV) Sporting Goods upgraded to Neutral from Underperform at Wedbush
Wedbush upgraded Big 5 following the company’s better than expected Q2 results and raised its target on shares to $14 from $9.
Nasdaq Composite
Pivot points for the $COMP. Pivot High: 2024.375, Pivot Low: 2002.525. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.
INO CLOSES 30 Million Funding Stocks flying
INO closes $30 mln registered direct offering
July 31 (Reuters) – Inovio Biomedical Corp: * Closes $30 million registered direct offering
AET , CI , HUM, UNH,WLP
All stocks in the managed health care are up form 2% to 8%
PIPE REPORT July 21, 2009
PIPE Volume Rose in 2nd Quarter, Compared With First
Posted July 21, 2009 12:00PM PST
The second quarter saw a promising increase in PIPE activity, as U.S.-listed companies raised $12.9 billion, or 63% more capital than they did in the first quarter, according to PrivateRaise, the data service of DealFlow Media. The number of deals rose 32% over the first quarter.
Major players in the PIPE market in the first half of the year included Iroquois Capital and Downsview Capital, the only fund managers to invest in more than 10 offerings; and Rodman & Renshaw, which placed 27 PIPEs, three times the number of placements by Lazard, the second most active placement agent. Investors who brought the most cash to the PIPE market were Berkshire Hathaway, which invested $3 billion in a private placement; Aabar Investments PJSC, with $2.6 billion; and Kuwait Investment Authority, with $1 billion. The companies that raised the most capital included four Dow Chemical, with $4 billion; BlackRock, Inc., with $2.8 billion; Daimler AG, with $2.5 billion; and ArcelorMittal, with $1.7 billion.
Data from the first half shows that PIPE financing activity has not returned to levels prevailing before the credit crunch of late 2008 and fickle securities markets depressed most forms of financing. The first half of 2009 saw a 44% drop in deal volume, compared with the year earlier period, and a 68% decline in total investment.
The third and fourth quarters could bring a further rebound towards last year’s numbers. In addition to increased deal flow, second quarter numbers reflect a growing trend in registered shelf offerings or “registered directs.” Companies raised $967.7 million in 57 registered direct offerings last quarter, compared to $417.9 million in 25 first quarter deals. While registered directs accounted for only about 7% of capital raised in the second quarter, the number of shelf statements filed in anticipation of future raises more than doubled from the same quarter last year. The 250 shelf statements filed in the second quarter of this year could be used to raise as much as $39 billion. As much as $72 billion could be raised from shelf statements filed during the entire first half of the year.
Even at the current level of activity they represent a fraction of the total PIPE market, and are not a viable option for the majority of emerging growth companies that remain ineligible for S-3 registration and must rely on the traditional PIPE market for equity capital.
Earnings on CTXS
Citrix Systems (CTXS) reports Q2 earnings after the market close on Wednesday, July 22, Citrix Systems to announce strong Q2 results,or above current expectations, and to maintain its FY09 guidance.
The core business held up reasonably well in the quarter, with William Blair estimated XenApp license revenues of $88M. The firm’s checks continue to indicate strong customer interest in desktop and client side virtualization, and it believes the company is well positioned to capitalize on this trend in the long term. However, despite its confidence that Citrix is likely to maintain full-year guidance
Wells Fargo (NYSE:WFC) is expected to report Q2 earnings before the market open on Wednesday, July. Analysts are looking for EPS of .34 on revenue of $18.95B. The consensus range for EPS is 0c to 50c, while the consensus range for revenue is $18.95B to $21.71B, according to First Call. A Sterne Agee analyst, reporting that he heard Wells had sold $600M of non-performing subprime loans for 35c on the dollar, recently predicted that Wells would have to raise more money through the equity markets. Last month S&P lowered the ratings of Wells and 21 other banks as the ratings agency predicts that operating conditions for the banking industry will become less favorable than in the past. June that Wells could report strong Q2 results. The firm said that Q2 estimates appeared to be low. The Citigroup analyst expected Wells to provide bullish guidance, although it maintained a Hold rating on the stock based on valuation. Also, the Q2 EPS of Wells peers JP Morgan (JPM), Bank of America (BAC) Goldman Sachs (GS), and Citigroup (C), beat expectations. JP Morgan and Citigroup said they saw improvements in the performance of the financial markets, while Goldman and Citigroup both said that the trading environment was favorable. Bank of America reported that it felt less constrained by macro economic factors. On the other hand, some analysts have been unenthusiastic about both banks’ fundamentals, and their stocks have fallen in recent days. (the Fly)
ECB Bancorp (Nasdaq:ECBC) reports Q2 EPS 19c vs.
More Action QLGC
QLogic (QLGC) to report Q1 earnings after the market close on Tuesday, July 21, with a conference call scheduled for 5:00 pm ET
NRG Energy on the move (NRG) $24.30 last
Misonix (MSON) awarded for forensic equipment in ChinaMisonix announced receipt of its first award for forensic equipment in China from the company’s distributor CSI Technology/CStrace International.
Equipment will be used by Chinese Law Enforcement in a major city in China. This award came from a competitive bid which focused on quality and performance.
Mid Day report
DuPont: Earnings release NYSE:DD
There is a bottom “W” pattern in progress on the daily chart. Look for DD to trade up to the $29 area, Better than expected .
Advance Micro upgraded to outperform NYSE:AMD
Stocks continue to rally into monday mid day. Stocks continued last week’s rally. All 3 of indices into green territory up 5%
Crude oil prices are up 0.5% and gold is basically flat.
Citigroup NYSE:C options active call option volume of 534,676 contracts compares to put volume of 414,924 contracts. C August 3 straddle at 59c, September 3 straddle at 74c. C over all option implied volatility of 52 is
HGSI Up $7.00 at ther open Trade of the day
Human Genome news on Phase III
Human Genome Sciences (HGSI) anounced that BENLYSTA met the primary endpoint in BLISS-52, the first of two Phase 3 trials. In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
Mid Day stocks
build your financial model here www.blattistics.com
Stocks rebounding.
Stocks are still lower but they’re off their worst levels of the session. Profit taking all day is the main reason.
Each sell off has brought out buyers. The averages have been establishing higher lows with each sell off and subsequent buying, setting up what could be a late day move towards positive territory. The Dow is down 70 to 9,250, the NASDAQ is down 25.50 to 1,985.85, and the S&P is down 6.75 to 998.90.
MOVERS
On2 Technologies (ONT) up 50% after announcing that it will be acquired by Google (GOOG)
Onyxx Pharmaceuticals (ONXX) is down over 14% after announcing concurent offerings of 4M shares of common stock and $200M in convertible senior notes.
INOVIO Biomedical (AMEX:INO) (INO) is still up in the $2.56 up over 25% on 15milion shares.
If you think inflation is coming back go long TBT. I plan to
Unusual options trading activity in Pfizer Inc. (NYSE: PFE).
As of 11:00 AM EST we have seen some 47,000 PFE AUG $13 CALLS traded today alone versus a prior open interest of a mere 120 contracts. Out in September expiration, we have seen 10,500 of the SEPT $11 Calls trade versus a prior open interest of 10 contracts.
August 5, 2009 at 9:51 am Leave a comment